All articles tagged with #ischemic optic neuropathy
A FAERS-based analysis of over 30 million adverse-event reports suggests Wegovy has the strongest association with ischemic optic neuropathy among semaglutide drugs, with higher signals in men and at higher Wegovy doses. While cases are rare and causation isn’t proven, researchers call for urgent prospective studies as GLP-1 obesity drugs become more widely used.
A British Journal of Ophthalmology study analyzed FDA adverse-event reports and found ischemic optic neuropathy (ION) in fewer than 1% of Wegovy users (28 of 3,070 reports) versus 47 of 20,608 for Ozempic, suggesting a possible Wegovy-specific signal but not proving causation. The data come from voluntary reports and don’t establish true risk; experts say the overall risk is very low and Wegovy’s benefits for weight management likely outweigh this potential issue. Regulators advise urgent medical care if eyesight worsens quickly, and Rybelsus showed no notable link in the study; dose differences remain unproven as a factor.
A FDA adverse-event database analysis (2017–2024) suggests Wegovy users have about 4.7 times higher odds of ischemic optic neuropathy than Ozempic users, with no clear link for Rybelsus; findings are associations, not definitive risk estimates for all patients, and researchers call for prospective studies to guide prescribing and policy.
A 44-year-old man in Taiwan went permanently blind in one eye after falling asleep face-down while drunk, causing pressure on his eye that led to blood vessel rupture and fluid buildup. He was diagnosed with ischemic optic neuropathy and choroidopathy, conditions that resulted in vision loss and eye tissue swelling. Despite receiving high-dose steroids, the man remained blind in his left eye after four months. The case report was published in the New England Journal of Medicine, highlighting the severe consequences of alcohol-related eye injuries.